DDInter233 DDInter1147
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Brigatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Brigatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ubrogepant
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Levonorgestrel
Brigatinib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Brigatinib may lead to a major life threatening interaction when taken with Levonorgestrel
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib